Atossa Genetics Inc (NASDAQ:ATOS) Short Interest Update
Atossa Genetics Inc (NASDAQ:ATOS) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 312,300 shares, a decline of 34.8% from the July 31st total of 478,800 shares. Based on an average daily trading volume, of 413,800 shares, the short-interest ratio is currently 0.8 days. Currently, 3.4% of the company’s stock are short sold.
NASDAQ ATOS traded down $0.01 on Friday, reaching $2.09. The stock had a trading volume of 8,936 shares, compared to its average volume of 68,927. The business has a 50 day moving average price of $2.11 and a 200 day moving average price of $2.46. Atossa Genetics has a 1 year low of $0.80 and a 1 year high of $7.39. The company has a market capitalization of $19.12 million, a price-to-earnings ratio of -0.38 and a beta of 3.29.
Atossa Genetics (NASDAQ:ATOS) last issued its earnings results on Tuesday, August 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.32). On average, research analysts forecast that Atossa Genetics will post -1.28 EPS for the current year.
An institutional investor recently raised its position in Atossa Genetics stock. Vanguard Group Inc. raised its position in Atossa Genetics Inc (NASDAQ:ATOS) by 73.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,689 shares of the company’s stock after purchasing an additional 51,200 shares during the quarter. Vanguard Group Inc. owned approximately 1.32% of Atossa Genetics worth $308,000 at the end of the most recent quarter. 2.65% of the stock is currently owned by institutional investors.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.